Syngene (established in 1993) as a Biocon subsidiary is India's first Contract Research Organization (CRO) which expanded later to be an integrated
Syngene International Ltd
-(SYNGENE)
XNSE:SYNGENE, XBOM:SYNGENE
Syngene International Ltd Q1FY25; 18% fall in Profits
Syngene (established in 1993) as a Biocon subsidiary is India's first Contract Research Organization (CRO) which expanded later to be an integrated
Syngene International Ltd Q4FY24; 6% rise in Profits
Syngene (established in 1993) as a Biocon subsidiary is India's first Contract Research Organization (CRO) which expanded later to be an integrated
Syngene International Ltd Q3FY24; 2% rise in Profits
Syngene (established in 1993) as a Biocon subsidiary is India's first Contract Research Organization (CRO) which expanded later to be an integrated
Syngene International Ltd Q2FY24; 14% rise in Profits
Syngene (established in 1993) as a Biocon subsidiary is India's first Contract Research Organization (CRO) which expanded later to be an integrated
Syngene International Ltd Q1FY24; 26% rise in Profits
Syngene (established in 1993) as a Biocon subsidiary is India's first Contract Research Organization (CRO) which expanded later to be an integrated
Syngene International Ltd (SYNGENE) Q4 FY23 Earnings Concall Transcript
Syngene International Ltd (NSE:SYNGENE) Q4 FY23 Earnings Concall dated Apr. 27, 2023. Corporate Participants: Avantika Mishra -- Investor Relations Jonathan Hunt -- Managing Director and Chief
Syngene reported 21 percent rise in its Q4FY23 net profit
Syngene reported Total revenue for Q4 FY23 of ₹994 Crore, up from ₹759 Crore year on year, a growth of 31%.While, consolidated
Syngene International Q4FY23 results out, revenue rises by 31%
Syngene (established in 1993) as a Biocon subsidiary is India's first Contract Research Organization (CRO) which expanded later to be an integrated
Syngene International Ltd (SYNGENE) Q3 FY23 Earnings Concall Transcript
Syngene International Ltd (NSE: SYNGENE) Q3 FY23 Earnings Concall dated Jan. 24, 2023 Corporate Participants: Avantika Mishra -- Associate - EY Jonathan Hunt -- Managing Director
Syngene reported a 5% rise in its net profit for Q3FY23
Syngene International reported a 5.5% rise in consolidated net profit to INR 109.70 crore in Q3 FY23 as against INR104 crore posted
Syngene International Ltd (SYNGENE) Q3 FY23 Earnings Concall Transcript
Syngene International Ltd (NSE: SYNGENE) Q3 FY23 Earnings Concall dated January 24, 2023 Corporate Participants: Avantika Mishra -- Associate - EY Jonathan Hunt -- Managing Director
Shares of Biocon research arm soars as it reports 23% rise in its revenue
Syngene International reported a 5.5% rise in consolidated net profit to INR 109.70 crore in Q3 FY23 as against INR104 crore posted
Syngene International Ltd (SYNGENE) Q2 FY23 Earnings Concall Transcript
Syngene International Ltd (NSE:SYNGENE) Q2 FY23 Earnings Concall dated Oct. 20, 2022 Corporate Participants: Avantika Mishra -- Investor Relations` Jonathan Hunt --
Syngene International Ltd Q1 FY23 Earnings Conference Call Insights
https://youtu.be/xL_nlERmIDQ Key highlights from Syngene International Ltd (SYNGENE) Q1 FY23 Earnings Concall Q&A Highlights: Prakash Agarwal from Axis Capital asked about the